Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data

The Lancet Regional Health - Western Pacific, Journal Year: 2023, Volume and Issue: 43, P. 100988 - 100988

Published: Dec. 18, 2023

Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of kidney failure and death in patients with chronic disease (CKD) but are underused. We evaluated number CKD Australia that would be eligible for treatment estimated cardiorenal events could averted improved uptake SGLT2 inhibitors.

Language: Английский

---

Does amino acid infusion reduce the risk of clinically significant acute kidney injury following cardiac surgery?

Journal of Cardiothoracic and Vascular Anesthesia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Transforming Traditional Industry Advisory Boards Into Mutually Beneficial Strategic Think Tanks: A Peer Review Council Case Series and Best Practices

Journal of Pharmaceutical Innovation, Journal Year: 2025, Volume and Issue: 20(1)

Published: Jan. 23, 2025

Language: Английский

---

Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study

BMC Primary Care, Journal Year: 2025, Volume and Issue: 26(1)

Published: Feb. 1, 2025

To describe the clinical characteristics, comorbidity, and medical treatment in a primary care population with chronic kidney disease (CKD). Additionally, to investigate how physicians (PCPs) diagnose, manage treat impaired function, including uptake of cardio-renoprotective renin-angiotensin-aldosterone system inhibitors (RAASis) sodium glucose co-transporter 2 (SGLT2is). An observational study CKD prevalence, patterns comorbidities based on patient record data combined questionnaire diagnosis, management function real-world, setting. In all 128 clinics Denmark 211 randomly invited quetionnaire completed by 125/128 participating PCPs. A computerized selection identified 12 random individuals per clinic ≥ measurements eGFR < 60 mL/min/1.73 m2 or UACR > 30 mg/g within two years (N = 1 497). Pre-specified collected from individual electronic health records included demographics, variables, comorbidities, relevant prescribed medications. Of 497), 80% had hypertension, 32% diabetes (DM), 13% heart failure (HF), 59% no DM/HF. ACEis/ARBs were 65%, statins 56%, SGTL2is 14%, MRAs 8% individuals. Treatment differed between varying e.g., usage was higher DM (76%) HF (74%) vs. DM/HF (58%), as statin (76% 45% DM/HF). SGTL2i low. Most PCPs using (62%) (58%) 62% reported initiating retard decline. Despite good PCP awareness wish use guidelines, gap exists implementation treatment, especially without This offers an opportunity for clear recommendations optimize early cardio-renal protection CKD.

Language: Английский

---

Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Chronic kidney disease (CKD) affects individual welfare, healthcare systems and societal progress. Of the multifaceted etiological factors, type 1 diabetes mellitus (T1DM) is a prominent contributor to CKD. We analysed global incidence, prevalence, deaths disability-adjusted life-years (DALYs) with age-standardised rates of CKD due T1DM (CKD-T1DM) in 2021, stratified by subtype. calculated temporal trends infirmity burden from 1990 2019 using linear regression model. The age-period-cohort (APC) Bayesian APC models predicted prospective over next 25 years. Sensitivity analysis was conducted Autoregressive Integrated Moving Average Exponential Smoothing models. Globally, there were 95 140 incidences, 6 295 711 prevalence cases, 94 020 3 875 628 DALYs CKD-T1DM. Males young-to-middle-aged individuals more likely be affected middle-socio-demographic index regions at higher risk. A considerable variation observed across Global Burden Disease super countries. number patients CKD-T1DM surged globally 2021. projections indicated continuous increase until 2046, driven ageing populations unmet therapeutic needs low-resource settings. poses growing public health threat, necessitating region-specific strategies that address inequities, promote early screening prioritise nephroprotective therapies among populations.

Language: Английский

---

Effectiveness of a systematic home-based albuminuria screening programme to detect chronic kidney disease in high-risk individuals in primary care (SALINE): a cross-sectional screening study

EClinicalMedicine, Journal Year: 2025, Volume and Issue: 82, P. 103185 - 103185

Published: April 1, 2025

Although guidelines recommend opportunistic screening for chronic kidney disease (CKD) in individuals with established risk factors, such as diabetes, hypertension, or cardiovascular disease, CKD these remains suboptimal. This study aimed to evaluate the effectiveness of a systematic home-based albuminuria program primary care patients at CKD. A cross-sectional was performed ten general practices and five pharmacies Netherlands from November 2021 May 2024. random selection aged 45-80 years based on factors registered their electronic medical record invited using urine collection device measurement urinary albumin-to-creatinine ratio (ACR). In those confirmed increased (ACR ≥3 mg/mmol), an elaborate assess presence performed, followed by referral practitioner (GP) evaluation findings. The outcome yield detect GP pharmacy setting. SALINE is ClinicalTrials.gov, NCT05321095. total, 6380 (3802 via GPs 2578 pharmacies) were screening. participation rate 40·1% among (1524/3802), compared 21·8% (562/2578) (P < 0·001). 8·7% participants had (133/1524), 6·0% (34/562). Of 115 detected who completed screening, 102 (88·7%) identified one more newly diagnosed factor(s) (n = 46, 40·0%), known factor that outside target range treatment 75, 65·2%). completing 26 those, 22 (84·6%) 6, 2·3%), 21, 80·8%). Systematic care, when addition regular has acceptable GPs, whereas it less effective pharmacies. Such identifies yet unknown may benefit starting optimizing cardioprotective treatment. introduction programs merits further optimize yield. funded AstraZeneca Netherlands.

Language: Английский

---

The interplay between heart failure and chronic kidney disease

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Abstract Chronic kidney disease (CKD) and heart failure (HF) are two globally prevalent, independent, long‐term conditions, which often coexist in an individual display a bidirectional yet interconnected relationship. The presence of CKD leads to the development HF vice versa, propagates worsening each disease, reflecting intertwined cycle. Both share common risk factors, such as increasing age, diabetes, high blood pressure, obesity smoking. Data show that approximately half all people with also have CKD, impacts patient burden quality life due significantly greater hospitalization death, compared those either or HF. To maximize treatment effectiveness individuals both healthcare professionals should recognize these diseases systemic representing organ‐specific manifestations similar underlying processes. It is essential understand role renin–angiotensin system inhibitors, sodium–glucose cotransporter 2 nonsteroidal mineralocorticoid receptor antagonist finerenone, glucagon‐like peptide‐1 agonists managing conditions. Lifestyle modifications be recommended. This review discusses factors contributing interplay between key providing appropriate for co‐existing diseases.

Language: Английский

---

High prevalence of unrecognized chronic kidney disease in the Lolland-Falster Health Study: a population-based study in a rural provincial area of Denmark

European Journal of Public Health, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Abstract Chronic kidney disease (CKD) affects 10–15% globally and is a marked independent risk factor for cardiovascular disease. Prevalence estimations are essential public health planning implementation of CKD treatment strategies. This study aimed to estimate the prevalence stages in population-based Lolland-Falster Health Study, set rural provincial area with lowest socioeconomic status Denmark. Additionally, characterized participants CKD, evaluated overall recognition, including awareness compared it other common conditions. Cross-sectional data were obtained from clinical examinations, biochemical analyses, questionnaires. was defined as albuminuria (urine albumin–creatinine ratio ≥30 mg/g), estimated glomerular filtration rate (eGFR) &lt;60 ml/min/1.73 m², or by diagnosis National Patient Register. assessed self-reported recognition either registered hospital CKD. Among 16 097 adults (median age 58.6 years), 18.0% (n = 2903), 70.1% identified albuminuria, 28.4% reduced eGFR, 1.5% alone. Of those 98.8% had 1–3 (eGFR m²), 1.2% 4–5 &lt;30 m²). Female sex, comorbidities, smoking, low parameters independently associated 4.4%, &gt;50% hypertension &gt;80% diabetes, (self-reported diagnosis) 7.1%. Thus, this study, highly prevalent but poorly recognized, indicating great potential preventing progression related complications.

Language: Английский

---

Association of Podometrics Findings in Patients With Hypertension and Type 2 Diabetes: A Retrospective Analysis

Hypertension, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

Arterial hypertension (HTN) and type 2 diabetes (T2DM) are contributors to chronic kidney disease leading glomerulomegaly podocyte loss. Enlarged glomeruli depletion associated with progression. This retrospective study aimed investigate morphometric changes in patients HTN the contribution of coexisting T2DM HTN. Glomerular structure was estimated stereologically unaffected areas tumor nephrectomies 99 patients. Morphometric features between subjects (n=47), HTN+T2DM (n=32), controls without (n=20) were compared by ANOVA. Linear regression models evaluated effect parameters on renal compensation after nephrectomy (change glomerular filtration rate from pre-nephrectomy 12 mo post-nephrectomy). In total, 36% 50% exhibited dipstick-positive proteinuria. volume similar (2.7±0.8 versus 2.3±0.8×106 µm³; P=0.16) only (2.7±0.9×106 P=0.95). Podocyte density reduced (217±66 279±75 per 106 P=0.02) not different (233±87 P=0.67). nuclear larger (230±28 201±32 P=0.004) (221±33 P=0.39). Larger (P=0.009), (P=0.003), hypertrophy (P=0.01) impaired compensation. The patterns independently observed both controls. Coexisting no additional alterations.

Language: Английский

---

Population Health Management for Improving Kidney Health Outcomes

American Journal of Kidney Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---